3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
7
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
71
Lymphoma, Large B-Cell, Diffuse
51
Neoplasms
41
Lymphoma, Non-Hodgkin
41
Multiple Myeloma
40
Lymphoma
37
Recurrence
35
Lymphoma, Follicular
30
Carcinoma, Non-Small-Cell Lung
30
Leukemia, Lymphocytic, Chronic, B-Cell
29
Lymphoma, B-Cell
26
Triple Negative Breast Neoplasms
23
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Ovarian Neoplasms
17
Lymphoma, Mantle-Cell
17
Pancreatic Neoplasms
15
Neoplasm Metastasis
15
Leukemia
15
Squamous Cell Carcinoma of Head and Neck
12
Melanoma
12
Stomach Neoplasms
11
Colorectal Neoplasms
11
Lymphoma, B-Cell, Marginal Zone
10
Prostatic Neoplasms
9
Head and Neck Neoplasms
9
Lymphoma, T-Cell, Peripheral
8
Liposarcoma, Myxoid
8
Carcinoma, Renal Cell
8
Sarcoma
7
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
Cyclophosphamide
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled